Details of the Drug Formulations

General Information of Drug (ID: DM48K0X)

• Drug Name: Carfilzomib Drug Info
• Synonyms: Carfilzomib; 868540-17-4; Kyprolis; Carfilzomib (PR-171); PR-171; UNII-72X6E3J5AR; 72X6E3J5AR; CHEMBL451887; CHEBI:65347; NCGC00249613-01; DSSTox_RID_82886; DSSTox_CID_28616; DSSTox_GSID_48690; (S)-4-methyl-N-((S)-1-(((S)-4-methyl-1-((R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)pentanamide; N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Plasma cell myeloma	2A83.1	Approved	[2]
Small-cell lung cancer	2C25.Y	Phase 1/2	[3]

• Cross-matching ID:
  PubChem CID: 11556711
  ChEBI ID: CHEBI:65347
  CAS Number: 868540-17-4
  TTD ID: D00UVA
  VARIDT ID: DR01324
  ACDINA ID: D00915

Full List of Drug Formulations Containing This Drug

Carfilzomib 60mg/vial powder

Company	Formulation ID	FDA Description
Onyx Therap	F24030	Sulfobutylether Beta-Cyclodextrin; Anhydrous Citric Acid

Carfilzomib 30mg/vial powder

Company	Formulation ID	FDA Description
Onyx Therap	F24031	Sulfobutylether Beta-Cyclodextrin; Anhydrous Citric Acid

Carfilzomib 10mg/vial powder

Company	Formulation ID	FDA Description
Onyx Therap	F24032	Sulfobutylether Beta-Cyclodextrin; Anhydrous Citric Acid

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7420).
• [2] Carfilzomib FDA Label
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)